Prospective observational study of biomarkers to predict efficacy after Pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer.
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000026793
- Lead Sponsor
- Gunma University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Judgement as exclusion by chief mdical physians having auto-immune diseases
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method